Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Charlottesville, Virginia Clinical Trials

A listing of Charlottesville, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (29) clinical trials

Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

Studies will be performed in early pubertal (late Tanner 1 [estradiol level > 20 pg/ml] to Tanner 3, premenarcheal) girls with and without hyperandrogenemia (HA). After a potential subject is identified by the Pediatric, Teen, or Endocrine clinics, she will come to the CRU or alternate UVA clinical unit for ...

Phase

5.55 miles

Learn More »

A Study of XmAb 18087 in Subjects With NET and GIST

This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with ...

Phase

5.55 miles

Learn More »

M6620 Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

PRIMARY OBJECTIVES: I. Assess the safety and tolerability of M6620 (VX-970) when administered along with weekly cisplatin and radiation therapy (XRT) in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC). II. Establish the recommended phase 2 dose (RP2D) of the combination. SECONDARY OBJECTIVES: I. Characterize the pharmacokinetic ...

Phase

5.55 miles

Learn More »

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of combination decitabine and ipilimumab for relapsed or refractory myelodysplastic syndrome (MDS) or relapsed or refractory acute myeloid leukemia (AML) in patients who are post allogeneic hematopoietic stem cell transplant (allo-HCT). II. To determine ...

Phase

5.55 miles

Learn More »

Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants

Aim1: To evaluate the safety and tolerability of three different lactoferrin doses in preterm infants Lactoferrin related adverse events and serious adverse events Number of infants reaching full feeds while receiving lactoferrin (120 ml/kg/day) Episodes of not receiving enteral feedings for > 24 hours once feeding is initiated Aim 2: ...

Phase

5.55 miles

Learn More »

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of osimertinib (AZD9291) in combination with navitoclax in patients with EGFR-mutant non-small cell lung cancer (NSCLC) following resistance to prior EGFR-tyrosine kinase inhibitor (EGFR TKI). II. To evaluate the feasibility of treatment with AZD9291 plus navitoclax for patients with T790M-mediated acquired ...

Phase

5.55 miles

Learn More »

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

During the follicular phase of the normal menstrual cycle, luteinizing hormone (LH) pulse frequency decreases during sleep. These decreases may be important to support follicle stimulating hormone (FSH) synthesis and secretion. Polycystic ovary syndrome (PCOS) is associated with a persistently rapid gonadotropin hormone-releasing hormone (GnRH) pulse frequency, an abnormality that ...

Phase

5.55 miles

Learn More »

Determining How Quickly Progesterone Slows LH Pulse Frequency

Studies under this protocol will be performed in normally cycling women and in women with PCOS from 18 to 35 years old. Criteria for PCOS will be (a) clinical and/or biochemical evidence of hyperandrogenism, (b) oligomenorrhea, and (b) the absence of clinical or biochemical evidence of other potential causes of ...

Phase

5.55 miles

Learn More »

Phase I EGFR BATs in Newly Diagnosed Glioblastoma

In addition to finding the safe dose of EGFR BATs, immune evaluations will be performed as delineated in the schedule of events to measure immune responses during all stages of treatment for GBM.

Phase

5.55 miles

Learn More »